Where does Abbie Celniker work?

Abbie Celniker is Partner at Third Rock Ventures and Board director at Nominal and Board director at Cedilla Therapeutics, Inc. and Board director at Rheos Medicines.

What does Abbie Celniker invest in?

Abbie Celniker invests in Biotech, Medical Devices.

What check size does Abbie Celniker write?

Abbie Celniker typically writes checks of $100K – $5M.

What boards does Abbie Celniker sit on?

Abbie Celniker holds tracked board seats at Abata Therapeutics, Cedilla Therapeutics, Inc., Eleven Biotherapeutics, Flare Therapeutics, Goldfinch BioPharma, Imaginab, Nominal, PanOptica, Rheos Medicines.

Where did Abbie Celniker go to school?

Abbie Celniker studied at University of Arizona College of Medicine – Tucson (PhD, Molecular Biology); UC San Diego (Bachelor of Sciences, Biology).

Abbie Celniker

InvestorFounder

Partner at Third Rock Ventures · Board director at Nominal · Board director at Cedilla Therapeutics, Inc. · Board director at Rheos Medicines

Massachusetts

Writes $100K – $5M checks · typically $1.5M

About

A biotech executive with over 30 years in senior R&D and leadership roles, she joined Third Rock Ventures in 2016, where she focuses on the formation, development, and strategy of portfolio companies. She previously served as CEO of Eleven Biotherapeutics and Taligen Therapeutics, and held senior roles at Novartis, Millennium Pharmaceuticals, and Wyeth.

Invests in

BiotechMedical Devices

Board director at Nominal

Intro paths

→

In turn, Abbie can intro founders to Nominal's investors below.

Nominal's investors · 43

AccelPalo Alto · $1.6M – $70M checks AdaverseHong Kong AlephTel Aviv · $2.5M – $100M checks Ascenta CapitalWilmington · since 2023 Axeleo CapitalParis · $108K – $1.6M checks Bluebird VenturesPalo Alto Bright Pixel CapitalLisbon CapitalGSan Francisco · $50M – $100M checks Centerview Capital TechnologyPalo Alto Collab+CurrencyEugene Dell Technologies CapitalPalo Alto · $500K – $50M checks Draft Ventures LlcSan Francisco Elevation CapitalGurugram · $1.5M – $37M checks Firebolt Ventures Management Company, LlcPalo Alto General CatalystSan Francisco · $30M checks · since 2024 Geodesic CapitalFoster City Harpoon VenturesSan Diego · $100K – $5M checks Hidden Variable CoreNew York · since 2021 Index VenturesSan Francisco · $540K – $10.8M checks Justin “3LAU” Blau Kleiner PerkinsMenlo Park · $500K – $15M checks LaunchBay CapitalLondon Lightspeed Venture PartnersMenlo Park · $1.7M – $87M checks · since 2022 Menlo VenturesSan Francisco · $1M – $20M checks · since 2017 Mighty CapitalSan Francisco Norwest Venture PartnersMenlo Park · $10M – $30M checks · since 2017 Pantera CapitalSan Francisco · $5M – $100M checks PeakAmsterdam · $275K – $4.4M checks Peterson VenturesSalt Lake City · $250K – $2.5M checks Prima MateriaHelsingborg · since 2025 Qualcomm VenturesSan Diego · $5M checks Ring CapitalParis · $540K – $16.2M checks Sapphire VenturesMenlo Park · $5M – $20M checks Script CapitalSan Francisco · $250K – $500K checks Sequoia CapitalMenlo Park · $4.4M – $214M checks · since 2025 Standard Crypto StripesNew York · since 2021 Tenaya CapitalPalo Alto · $5M – $10M checks · since 2017 Third Rock VenturesBoston · $100K – $5M checks · since 2021 Together FundBangalore · $1M – $10M checks Valkyrie Ventures Management, LlcPark City Vesey VenturesWestport Z47Coral Springs · $1.2M – $40M checks

Co-founders at Nominal

Oren HarnevoExecutive Officer, Director

Ronald Bianchini, Jr.Executive Officer, Director

Roneil RumburgCofounder

Board director at Cedilla Therapeutics, Inc.

Intro paths

→

In turn, Abbie can intro founders to Cedilla Therapeutics, Inc.'s investors below.

Cedilla Therapeutics, Inc.'s investors · 2

Casdin CapitalNew York · since 2021 Third Rock VenturesBoston · $100K – $5M checks · since 2020

Board director at Rheos Medicines

Intro paths

→

In turn, Abbie can intro founders to Rheos Medicines's investors below.

Rheos Medicines's investors · 1

Third Rock VenturesBoston · $100K – $5M checks · since 2018

Experience

Third Rock VenturesPartnercurrent2016 — present
Eleven BiotherapeuticsCEO2011 — 2016Cambridge, MA
Alexion PharmaceuticalsSVP, Translational Medicine2011
Taligen Therapeutics Inc.CEO2006 — 2011
NovartisGlobal Head of Biologics2006 — 2008
Millennium Pharmaceuticals, Inc.SVP, Pharmacuetical Sciences and Strategy and Operations2000 — 2006
Wyeth BiotechVP Protein Technologies1998 — 2000
Genetics InstituteDirector, Antibody Technologies and Bioanalytical Sciences1993 — 1998
GenentechAssociate Director, Biological Assay Development1986 — 1993

Education

University of Arizona College of Medicine – TucsonPhD, Molecular Biology1981 — 1986
UC San DiegoBachelor of Sciences, Biology1976 — 1980

Skills & more

InflammationBiopharmaceuticals5GLPAntibodiesLifesciencesScienceBiotechnology2Protein Chemistry1Biologics2Assay DevelopmentClinical Development4Drug Discovery1

+12 more

PharmacologyTranslational MedicineBioanalysisLife SciencesDrug DevelopmentTechnology TransferMolecular BiologyCommercializationPharmaceutical IndustryStrategyTeam LeadershipImmunology

From Abbie's professional profile.

Deals · 7

NominalBoard seat

via Third Rock Ventures · filed Jun 2022 · $95M raise

Cedilla Therapeutics, Inc.Board seat

via Third Rock Ventures · filed Oct 2021 · $82.6M raise

Goldfinch BioPharmaBoard seat

via Third Rock Ventures · filed Jul 2020

PanOpticaBoard seat

via Third Rock Ventures · filed Apr 2019 · $47.3M raise

Rheos MedicinesBoard seat

via Third Rock Ventures · filed Nov 2018

Eleven BiotherapeuticsBoard seat

via Third Rock Ventures · filed Apr 2018 · $996K raise

ImaginabBoard seat

via Third Rock Ventures · filed Apr 2016 · $9.5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Abata TherapeuticsFlare Therapeutics

Sources: the firm's website · SEC Form D filings.

Colleagues at Third Rock Ventures

Adam Tebbe

Investor at Third Rock Ventures

Alan Ezekowitz

Investor at Third Rock Ventures

Alison Connors

Investor at Third Rock Ventures

Amanda Chan

Investor at Third Rock Ventures

Andrea van Elsas

Investor at Third Rock Ventures

Andrew Warren

Senior Associate at Third Rock Ventures

Angelo Severino

Investor at Third Rock Ventures

Ava Brunelle

Investor at Third Rock Ventures

Network11

Alan Ezekowitz

Investor at Third Rock Ventures

Andrea van Elsas

Investor at Third Rock Ventures

Andrew Warren

Senior Associate at Third Rock Ventures

Barbara Weber

Venture Partner at Third Rock Ventures

Beryl Cummings

Senior Associate at Third Rock Ventures

Cary Pfeffer

Investor at Third Rock Ventures

Charles Homcy

Investor at Third Rock Ventures

Christoph Lengauer

CSO at Curie.Bio

Craig Muir

Investor at Third Rock Ventures

David Kaufman

Investor at Third Rock Ventures

George Xu

Senior Associate at Third Rock Ventures

Investors connected to Abbie in public investor directories — a warm-intro map.

Frequently asked questions

Who is Abbie Celniker?: A biotech executive with over 30 years in senior R&D and leadership roles, she joined Third Rock Ventures in 2016, where she focuses on the formation, development, and strategy of portfolio companies. She previously served as CEO of Eleven Biotherapeutics and Taligen Therapeutics, and held senior roles at Novartis, Millennium Pharmaceuticals, and Wyeth.
Where does Abbie Celniker work?: Abbie Celniker is Partner at Third Rock Ventures and Board director at Nominal and Board director at Cedilla Therapeutics, Inc. and Board director at Rheos Medicines.
What does Abbie Celniker invest in?: Abbie Celniker invests in Biotech, Medical Devices.
What check size does Abbie Celniker write?: Abbie Celniker typically writes checks of $100K – $5M.
What boards does Abbie Celniker sit on?: Abbie Celniker holds tracked board seats at Abata Therapeutics, Cedilla Therapeutics, Inc., Eleven Biotherapeutics, Flare Therapeutics, Goldfinch BioPharma, Imaginab, Nominal, PanOptica, Rheos Medicines.
Where did Abbie Celniker go to school?: Abbie Celniker studied at University of Arizona College of Medicine – Tucson (PhD, Molecular Biology); UC San Diego (Bachelor of Sciences, Biology).